Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 2025 ASCO Annual Meeting in Chicago. The company will host a live webcast on June 1, 2025, at 6:00 p.m. CT, featuring CEO Ying Huang and CMO Mythili Koneru, who will be joined by expert clinicians to discuss updates from the CARTITUDE development program. Investors can access the webcast through a provided weblink or the company's website under Events and Presentations.
Legend Biotech (NASDAQ: LEGN) ha annunciato un prossimo evento per investitori durante il 2025 ASCO Annual Meeting a Chicago. L'azienda trasmetterà una diretta web il 1 giugno 2025 alle 18:00 CT, con la partecipazione del CEO Ying Huang e della CMO Mythili Koneru, accompagnati da esperti clinici per discutere gli aggiornamenti del programma di sviluppo CARTITUDE. Gli investitori potranno accedere alla diretta tramite un link fornito o dal sito web aziendale nella sezione Eventi e Presentazioni.
Legend Biotech (NASDAQ: LEGN) ha anunciado un próximo evento para inversores durante la Reunión Anual ASCO 2025 en Chicago. La compañía realizará una transmisión en vivo el 1 de junio de 2025 a las 6:00 p.m. CT, con la participación del CEO Ying Huang y la CMO Mythili Koneru, quienes estarán acompañados por expertos clínicos para discutir novedades del programa de desarrollo CARTITUDE. Los inversores podrán acceder a la transmisión a través de un enlace proporcionado o en la sección de Eventos y Presentaciones del sitio web de la compañía.
Legend Biotech (NASDAQ: LEGN)는 시카고에서 개최되는 2025 ASCO 연례 회의 기간 중 투자자 대상 행사를 발표했습니다. 회사는 2025년 6월 1일 오후 6시 CT에 CEO Ying Huang과 CMO Mythili Koneru가 참석하며, 전문가 임상진들과 함께 CARTITUDE 개발 프로그램의 최신 정보를 논의하는 생중계 웹캐스트를 진행할 예정입니다. 투자자들은 제공된 웹링크 또는 회사 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 웹캐스트에 접속할 수 있습니다.
Legend Biotech (NASDAQ : LEGN) a annoncé un prochain événement pour les investisseurs lors du 2025 ASCO Annual Meeting à Chicago. La société organisera une diffusion en direct le 1er juin 2025 à 18h00 CT, avec la participation du PDG Ying Huang et de la directrice médicale Mythili Koneru, accompagnés d’experts cliniciens pour discuter des mises à jour du programme de développement CARTITUDE. Les investisseurs pourront accéder à la diffusion via un lien fourni ou sur le site web de l'entreprise dans la section Événements et Présentations.
Legend Biotech (NASDAQ: LEGN) hat eine bevorstehende Investorenveranstaltung während des 2025 ASCO Annual Meeting in Chicago angekündigt. Das Unternehmen wird am 1. Juni 2025 um 18:00 Uhr CT einen Live-Webcast veranstalten, bei dem CEO Ying Huang und CMO Mythili Koneru zusammen mit Experten aus der Klinik Updates zum CARTITUDE-Entwicklungsprogramm präsentieren. Investoren können über einen bereitgestellten Link oder die Unternehmenswebsite unter Veranstaltungen und Präsentationen auf den Webcast zugreifen.
- None.
- None.
SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program.
Investors and other interested parties may join the live webcast through this weblink or visit Legend Biotech’s website under Events and Presentations.
About Legend Biotech
With over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
When is Legend Biotech's investor event at ASCO 2025?
What will be discussed at Legend Biotech's ASCO 2025 investor event?
How can investors access Legend Biotech's ASCO 2025 presentation?
Who are the key speakers at Legend Biotech's ASCO 2025 investor event?
